ISM8969 (NLRP3 inhibitor)
Insilico Medicine (co-development with Hygtia Therapeutics): company profile
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
ISM8969 is a NLRP3 inhibitor from Insilico Medicine (co-development with Hygtia Therapeutics). The source describes it as small molecule (oral, brain-penetrant). It is being developed for chronic neuroinflammation, including Parkinson's disease (company goal); the Phase 1 trial enrolls healthy adults and obese adults at cardiovascular risk. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT07581431. The AI role named in the source is molecule design. Registry records: NCT07581431, Phase 1, recruiting, updated Jun 22, 2026. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. First-in-human dosing completed (June 2026) in an Australian SAD/MAD study in 80 healthy participants and 20 obese adults at cardiovascular risk; no data yet. The latest dated source is from Jun 17, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine (co-development with Hygtia Therapeutics)
- Indication
- Chronic neuroinflammation, including Parkinson's disease (company goal); the Phase 1 trial enrolls healthy adults and obese adults at cardiovascular risk
- Therapeutic area
- Neurology
- Modality
- Small molecule (oral, brain-penetrant)
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Jun 17, 2026
- Phase source
- Confirmed
- Board column
- Phase 1
Key readouts in the source
First-in-human dosing completed (June 2026) in an Australian SAD/MAD study in 80 healthy participants and 20 obese adults at cardiovascular risk; no data yet.
AI evidence
AI source: Company
“Advancing ISM8969 from an AI-generated concept to first-in-human dosing”
Trial records
- NCT07581431 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
NCT07581431 first posted on ClinicalTrials.gov
-
Company release: Phase 1
First-in-human dosing completed (June 2026) in an Australian SAD/MAD study in 80 healthy participants and 20 obese adults at cardiovascular risk; no data yet.
-
NCT07581431 record updated
Phase 1, Recruiting
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.